AbCellera Biologics (ABCL) EBITDA Margin (2020 - 2026)
AbCellera Biologics (ABCL) posted EBITDA Margin of 691.75% for Q1 2026, down 985.55% on a QoQ basis from 63.72% in Q4 2025, and up 78783.0% year-over-year from N/an in Q1 2025.
AbCellera Biologics (ABCL) EBITDA Margin (2020 - 2026) Analysis & Trends
AbCellera Biologics' EBITDA Margin history runs 7 years deep, the most recent figure standing at 691.75% for Q1 2026.
- Quarterly EBITDA Margin rose 78783.0% year-over-year to 691.75% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 267.61% (up 112773.0% YoY) and the FY2025 annual result came in at 288.98%, up 80271.0% from the prior year.
- EBITDA Margin was 691.75% for Q1 2026 at AbCellera Biologics, down from 63.72% in the prior quarter.
- Across five years, EBITDA Margin topped out at 71.06% in Q1 2022 and bottomed at 1479.57% in Q1 2025.
- A 5-year average of 633.22% and a median of 551.48% in 2024 frame the typical range for EBITDA Margin.
- Peak annual rise in EBITDA Margin reached 137697 bps in 2025, while the deepest fall reached 92810 bps in 2025.
- AbCellera Biologics' EBITDA Margin stood at 175.34% in 2022, then sank by 310 bps to 719.61% in 2023, then tumbled by 100 bps to 1440.69% in 2024, then soared by 96 bps to 63.72% in 2025, then tumbled by 986 bps to 691.75% in 2026.
- Business Quant data shows ABCL's EBITDA Margin at 691.75% in Q1 2026, 63.72% in Q4 2025, and 851.79% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 16.51% |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 38.10% |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 17.83% |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 30.35% |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | AbCellera Biologics | 1.62 Bn | 1.62 Bn | - | -691.75% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -691.75% |
| Dec 31, 2025 | -63.72% |
| Sep 30, 2025 | -851.79% |
| Jun 30, 2025 | -290.24% |
| Mar 31, 2025 | -1,479.57% |
| Dec 31, 2024 | -1,440.69% |
| Sep 30, 2024 | -1,439.42% |
| Jun 30, 2024 | -1,276.17% |
| Mar 31, 2024 | -551.48% |
| Dec 31, 2023 | -719.61% |
| Sep 30, 2023 | -831.79% |
| Jun 30, 2023 | -511.03% |
| Mar 31, 2023 | -532.10% |
| Dec 31, 2022 | -175.34% |
| Sep 30, 2022 | 37.22% |
| Jun 30, 2022 | -18.29% |
| Mar 31, 2022 | 71.06% |
| Dec 31, 2021 | 58.53% |
| Sep 30, 2021 | -510.09% |
| Jun 30, 2021 | -25.44% |